Feasibility of Neoadjuvant Immune Checkpoint Blockade for Resectable Diffuse Pleural Mesothelioma Along Potential of ctDNA Analyses to Detect Residual Disease By Ogkologos - September 22, 2025 231 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a phase II study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR ESMO World Congress on Gastrointestinal Cancer 2021, 30 June – 3... June 23, 2021 Monoclonal Antibodies May Lower Recurrence Risk for Some Early Stage Breast... February 2, 2022 “Oncometabolite” Neutralizes Immune Cells Near Tumors November 18, 2022 Genetic Testing for Bladder Cancer: What People With Cancer and Their... March 23, 2023 Load more HOT NEWS Real-World Patients with Cancer Show Lower Survival Times and Treatment-Associated Survival... Young Adult Cancer Awareness Week: Recognizing Adolescent and Young Adults Cancer... What Are Clinical Practice Guidelines and How Do They Impact Care... Breaking down changes in NHS cancer waiting times in England
